Blood

identifying appropriate public and private funding sources.CAR T-cell therapy for AML continues to face unique, complex challenges including target selection, design, toxicity prevention/management in a vulnerable patient population, and coordination with alloHCT.VBP301, although terminated early, illustrates the feasibility of manufacturing and delivering donorderived CAR T cells for patients wi…

Diffuse large B cell lymphoma (DLBCL) is a highly heterogenous malignant disease that remains a major clinical challenge as relapsed and refractory disease is difficult to treat. Apoptosis evasion is a major feature of DLBCL. However, while the suppression of intrinsic apoptosis has long been recognized as a lymphoma-promoting event, the role of extrinsic apoptosis has remained poorly defined. He…

In this issue ofBlood, Waliullah et al 1 identified a novel feed-forward loop (FFL) that is induced by transcription factor (TF) CCAAT enhancer-binding protein (C/EBP).This FFL is composed of TF PU.1 (SPI1) and the long noncoding RNA (lncRNA) LOUP (also known as SLC39A13-AS1), which drives monocyte/macrophage (Mo/M) differentiation and innate immune function (see figure).The gene encoding LOUP is…

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by monoclonal IgM autoantibodies that bind to red blood cells and trigger hemolysis through activation of the classical complement pathway. Cold agglutinins are produced by a clonal population of lymphocytes recognized by the WHO as a low grade lymphoproliferative disorder. Traditional therapy relied on B-cell-targeted imm…

Fixed-duration venetoclax combinations have become a standard first-line treatment in chronic lymphocytic leukemia (CLL). The phase 3 CLL13/GAIA trial assesses three time-limited combinations: venetoclax-rituximab (RV), venetoclax-obinutuzumab (GV), and venetoclax-obinutuzumab-ibrutinib (GIV) compared to chemoimmunotherapy (CIT). Fit patients with CLL without TP53 aberrations were randomized betw…

The process of non-occlusive thrombus formation is well known, but the mechanism keeping the thrombus silent at the end stage remains unclear. The aim of this work was to evaluate the role of fibrin in limiting further growth of a thrombotic remnant. Intravital microscopy showed that attachment of platelets to a fibrin-rich thrombus stopped after partial thrombus disaggregation, indicating that t…

Large scale sequencing efforts have defined up to 27 diagnostic entities in B-ALL, leaving few samples without subtype assignment. Extended genomic and transcriptomic profiling in routine diagnostics broadens the sample collection and holds the potential to identify novel B-ALL subtypes. By analyzing an aggregated set of 4,857 B-ALL patients from three cohorts, we identified a novel group of twen…

In this issue of Blood, Nishimura et al 1 demonstrate that expression of NUTM1 fusion genes in hematopoietic progenitors can induce a "one-hit leukemia" by driving differentiation to highly proliferating, stem-like B-cell progenitors.

targeting these eRNAs with ASOs can disrupt NIPBL interactions, and promoter recruitment to the ACH, resulting in BCL11A gene silencing and derepression of -globin to a remarkable degree.